Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

The emerging promise of liquid biopsies in solid tumors

Nature Cancer volume 3, pages 1420–1422 (2022)Cite this article

Subjects

Liquid biopsies of circulating tumor DNA offer a non-invasive tool with many potential applications in oncology, including early cancer detection, profiling, disease prognosis, prediction of therapy response and monitoring disease status. A growing body of literature and clinical trials support an increasingly valuable role for liquid biopsies in the care of patients with solid malignancies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Bohers, E., Viailly, P.-J. & Jardin, F. Pharmaceuticals 14, 596 (2021).

    Article  CAS  Google Scholar 

  2. Rothwell, D. G. et al. Nat. Med. 25, 738–743 (2019).

    Article  CAS  Google Scholar 

  3. Bidard, F.-C. et al. Lancet Oncol. 23, 1367–1377 (2022).

    Article  CAS  Google Scholar 

  4. Peters, S. et al. Nat. Med. 28, 1831–1839 (2022).

    Article  CAS  Google Scholar 

  5. Sartore-Bianchi, A. et al. Nat. Med. 28, 1612–1618 (2022).

    Article  CAS  Google Scholar 

  6. O’Leary, B. et al. Nat. Commun. 9, 896 (2018).

    Article  Google Scholar 

  7. Chera, B. S. et al. J. Clin. Oncol. 38, 1050–1058 (2020).

    Article  CAS  Google Scholar 

  8. Lipsyc-Sharf, M. et al. J. Clin. Oncol. 40, 2408–2419 (2022).

    Article  CAS  Google Scholar 

  9. Kotaka, M. et al. J. Clin. Oncol. 40, 9–9 (2022).

    Article  Google Scholar 

  10. Tie, J. et al. N. Engl. J. Med. 386, 2261–2272 (2022).

    Article  CAS  Google Scholar 

  11. Powles, T. et al. Nature 595, 432–437 (2021).

    Article  CAS  Google Scholar 

  12. Darbeheshti, F., Yu, F., Ahmed, F., Adalsteinsson, V. A. & Makrigiorgos, G. M. Clin. Chem. 68, 1250–1260 (2022).

    Article  Google Scholar 

  13. Lennon, A. M. et al. Science 369, eabb9601 (2020).

    Article  CAS  Google Scholar 

  14. Mathios, D. et al. Nat. Commun. 12, 5060 (2021).

    Article  CAS  Google Scholar 

  15. Schrag, D. et al. Ann. Oncol. 33, S417–S426 (2022). suppl. 7.

    Article  Google Scholar 

Download references

Author information

Author notes

  1. These authors contributed equally: Viktor A. Adalsteinsson, Aparna R. Parikh

Authors and Affiliations

  1. Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA

    Leontios Pappas & Aparna R. Parikh

  2. Broad Institute of MIT and Harvard, Cambridge, MA, USA

    Viktor A. Adalsteinsson

Authors
  1. Leontios Pappas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Viktor A. Adalsteinsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Aparna R. Parikh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Viktor A. Adalsteinsson or Aparna R. Parikh.

Ethics declarations

Competing interests

A.R.P. reports equity in C2i Genomics XGenomes and Parithera, and in the past 36 months, has served as an advisor/consultant for Eli Lilly, Pfizer, Inivata, Biofidelity, Natera, Checkmate Pharmaceuticals, FMI, Guardant, Abbvie, Bayer, Delcath, Taiho, CVS, Value Analytics Lab, Seagen, Inivata Saga and Scarce Illumnia. She receives fees from Up to Date. She has been on the Data and Safety Monitoring Committee for a Roche study and on the Steering Committee for Exilixis. She has received research funding to the Institution from PureTech, PMV Pharmaceuticals, Plexxicon, Takeda, BMS, Mirati, Novartis, Erasca, Genentech and Daiichi Sankyo. V.A.A. reports patient applications filed on liquid biopsy sequencing and analysis methods.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pappas, L., Adalsteinsson, V.A. & Parikh, A.R. The emerging promise of liquid biopsies in solid tumors. Nat Cancer 3, 1420–1422 (2022). https://doi.org/10.1038/s43018-022-00498-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-022-00498-4

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer